SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John H. Farro who wrote (1734)2/14/1997 8:26:00 PM
From: Richard Mazzarella   of 4342
 
Robin, Chris wrote <<--Assuming a 3.8% penetration of all AIDS patients
in the first year on the market, AndroVir could generate $2.4 mill. in sales
and make a $1.2 mill. profit contribution to PRLN. Likewise, AndroCar, the
drug to enhance the well-being of cancer patients, is assumed to penetrate
1.9% of the cancer market (as measured by number of patients) in its first
year, generating $4.0 mill. in sales and $1.6 mill. in profit for PRLN.
Potential markets are $300 mill. and $400 mill., respectively.>>

Profit to me means bottom line, not cash flow. Sales-expense=profit. Warrants would be used only for a couple of years for burn until they get increased profits occurring. Look at the potential markets above.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News